Lion Biotech Reports Positives Results For TIL With Ipilimumab Inhibitor

(RTTNews) - Lion Biotechnologies, Inc. (LBIO), Monday announced a positive results from a pilot trial on tumor infiltrating lymphocytes therapy or TIL in combination with ipilimumab inhibitor in patients with metastatic melanoma. The trial was partially sponsored by Lion and Phase 1 trial was conducted at Moffitt Cancer Center.

The trial to assess safety and feasibility of combining TIL therapy with the CTLA-4 checkpoint inhibitor and ipilimumab was done in 12 patients with metastatic melanoma. Patients were treated with ipilimumab one week prior to tumor harvest for TIL expansion, a second time while their TIL were being expanded, and two more times following TIL transfer.

The company said 46 percent of patients responded to the treatment and response rates were in line with previous TIL studies and there were higher patient adherence to trial protocol.